IL31RA抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cells, Primary antibody: P08440(IL31RA Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08440(IL31RA Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08440(IL31RA Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

Interleukin-31 receptor alpha (IL31RA) is a key component of the IL-31 signaling pathway, which plays a critical role in mediating pruritus (itch) and inflammatory responses. As a type I cytokine receptor, IL31RA pairs with the oncostatin M receptor beta (OSMRβ) to form a functional heterodimeric receptor complex. IL-31. the cytokine ligand, is primarily produced by Th2 cells and activates downstream JAK/STAT, MAPK, and PI3K/AKT pathways upon binding. This signaling cascade promotes sensory nerve sensitization, skin barrier dysfunction, and immune cell recruitment, making it a central driver in pruritic and inflammatory skin disorders like atopic dermatitis (AD), prurigo nodularis, and allergic contact dermatitis.

IL31RA-targeting antibodies are designed to block IL-31/IL31RA interactions, thereby inhibiting pro-inflammatory and itch-inducing signals. Preclinical studies demonstrate that anti-IL31RA antibodies reduce scratching behavior, epidermal thickening, and immune cell infiltration in disease models. Clinical trials of humanized IL31RA antibodies (e.g., nemolizumab) have shown significant efficacy in alleviating pruritus and lesion severity in AD patients, with some achieving Phase III development. These biologics offer a targeted approach for chronic itch management, addressing an unmet need in dermatology. Ongoing research explores their potential in eosinophilic disorders and neuropathic itch, while combination therapies with other biologics (e.g., dupilumab) are being investigated to enhance therapeutic outcomes.